BioSpace News Archive

Drug Development

Mirati’s Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients

San Diego-based Mirati Therapeutics, a clinical-stage biotechnology company, is currently developing sitravatinib to address unmet medical needs in cancer care.

September 20, 2020
·
3 min read
·
Brandon May
Progentec’s Novel Blood Test Predicts Lupus Flares Up to 12 Weeks Before They Occur

Progentec Diagnostics, Inc. just launched a novel blood test to determine the likelihood that a patient with systemic lupus erythematosus (commonly known as both SLE and lupus) will experience an immunologic disease flare during the coming 12 weeks.

September 20, 2020
·
4 min read
·
Gail Dutton
Drug Development

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology

Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”)

September 20, 2020
·
11 min read
Biotech Beach

Sotorasib (AMG 510) Shows Promising Results in Some Patients With Solid Tumors, Suggests a Study With City of Hope as a Co-Lead Author

Participants with advance non-small cell lung cancer and colorectal cancer experienced the greatest benefits in this first-in-human phase 1 clinical trial.

September 20, 2020
·
5 min read
Drug Development

Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine

Confirmed and Durable Anticancer Activity in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients From Phase 1 Trial

September 20, 2020
·
15 min read
Policy

Statement from the Chief Public Health Officer of Canada on September 20, 2020

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

September 20, 2020
·
2 min read
Pharm Country

Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020

New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy

September 20, 2020
·
55 min read
Pharm Country

Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020

Researchers Share New Data for Vibostolimab (MK-7684), Merck’s Anti-TIGIT Therapy, as Monotherapy and in Combination With KEYTRUDA® (pembrolizumab); First-Time Results for First-in-Class MK-4830 (Anti-ILT4 Therapy); and Late-Breaking Data for MK-6482 (HIF-2α Inhibitor)

September 20, 2020
·
41 min read
BioMidwest

Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

Verzenio in combination with endocrine therapy is the only CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in invasive disease-free survival (IDFS) in early breast cancer

September 20, 2020
·
21 min read
Genetown

Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer

60% ORR in patients previously treated with vandetanib or cabozantinib, and 74% ORR in treatment-naïve patients

September 20, 2020
·
12 min read